FDA Approves VYBRIQUE, First Sildenafil Oral Film for Erectile Dysfunction Treatment
核心洞察
The FDA has approved VYBRIQUE (搜索), the first sildenafil oral film for treating erectile dysfunction (搜索) in men aged 18 and older, offering a discreet treatment option that dissolves on the tongue without water.
A phase 3 randomized trial with 475 adult men demonstrated superior improvements in sexual function compared to placebo, with peak plasma concentrations reached between 30-300 minutes.
The oral film is available in four dosage strengths and will be commercially available in March 2026, with direct home delivery options across all states.
The FDA has approved VYBRIQUE (搜索), the first sildenafil oral film for treating erectile dysfunction (搜索) (ED) in men aged 18 years and older, IBSA USA (搜索) announced. This novel formulation represents a significant advancement in ED treatment delivery, offering patients a discreet alternative to traditional oral tablets.
Novel Drug Delivery Technology
VYBRIQUE (搜索) utilizes IBSA's innovative FilmTec® technology, creating a single-dose film that dissolves on the tongue without requiring water or other liquids. The oral film can be taken anywhere from 30 minutes to 4 hours before sexual activity and can be administered with or without food, providing flexibility for patients.
"Providing a treatment option that is discreet and easy to administer supports men in managing ED in a way that feels approachable and respectful of their sexual health," said Ralph M. Zagha, MD, from Precision Clinical Research.
Clinical Trial Results
The approval is supported by findings from a phase 3 randomized, double-blind, placebo-controlled trial (NCT05490680) that enrolled 475 adult men with ED across clinical trial sites in the US. The 12-week flexible-dose study evaluated VYBRIQUE (搜索) at doses of 25 mg, 50 mg, 75 mg, and 100 mg.
Participants were stratified by age for initial dosing: patients younger than 65 years received a starting dose of 50 mg, while patients 65 years and older received a starting dose of 25 mg. The flexible-dose design allowed for dosage adjustments based on individual patient response.
The study met its co-primary endpoints, demonstrating that VYBRIQUE (搜索) provided superior improvements in sexual function compared to placebo at Week 4. Pharmacokinetic analyses revealed that peak plasma concentrations were reached between 30 and 300 minutes under fasting conditions, with a median time to peak of 80 minutes.
Addressing Unmet Medical Needs
Erectile dysfunction (搜索) affects an estimated 30 to 50 million men in the United States, with increasing prevalence among younger populations. Research indicates that beyond age-related factors, anxiety (搜索), depression (搜索), and stress can contribute to ED development.
"While awareness and open discussion around ED have grown, it's still a sensitive topic where many men value discretion," said Nicholas Hart, IBSA USA (搜索) CEO. "The FDA approval of VYBRIQUE (搜索) provides men experiencing ED with a novel treatment option that helps meet the evolving needs of patients today."
Commercial Availability and Access
VYBRIQUE (搜索) is approved in four dosage strengths (25, 50, 75, and 100 mg), allowing for tailored therapy based on individual patient needs. The sildenafil oral film is expected to be commercially available in the US in March 2026, with direct home delivery available in all states to provide patients with convenient fulfillment options.
Safety Profile
VYBRIQUE (搜索) carries important safety considerations consistent with sildenafil-containing medications. The drug can cause dangerous blood pressure drops when taken with nitrates or guanylate cyclase stimulators. Serious side effects include priapism (搜索) (erections lasting more than 4 hours), sudden vision loss (搜索), and sudden hearing decrease or loss.
Common side effects observed include headache, flushing, upset stomach, stuffy or runny nose, and dizziness. Additional reported effects include abnormal vision, back pain, muscle pain, nausea, and rash.